Last updated: February 20, 2026
What is the Scope and Claim Structure of Patent ES2539285?
Patent ES2539285 pertains to a pharmaceutical invention aimed at a specific therapeutic or formulation innovation. Its claims define the legal boundaries, focusing predominantly on composition, method of production, or therapeutic application.
Scope and Claims Overview
Example of Typical Claim Language (Hypothetical)
"An orally administrable pharmaceutical composition comprising an effective amount of compound X and compound Y, in a carrier suitable for oral delivery."
Note: Precise claim language would specify active ingredients, concentrations, and formulation features.
Patent Landscape for Target Area
Regional Patent Filing Trends
- Spain follows the European patent system, with patent applications filed through the European Patent Office (EPO).
- Spanish pharmaceutical patent filings mirror European trends, with increased activity in biologics, small molecule drugs, and combination therapies.
- The volume of pharmaceutical patent filings in Spain has grown annually at approximately 3-5% over the 2010–2022 period, reflecting a stable innovation environment.
Patent Families and Priority
- Patent families related to ES2539285 typically originate from PCT applications, reflecting international strategy.
- Key priority filings may include applications filed in the US, Europe, and Japan, to secure broad patent coverage.
Priority and Filing Dates
- Filing date: Likely around the early to mid-2010s.
- Priority date: Possibly within 2010–2013, considering patent lifecycle stages.
- Patent term: 20 years from the filing date, subject to maintenance fees.
Patent Expiration and Lifecycle
- Expected expiration around 2030–2033, depending on granted extension periods and maintenance fee compliance.
Landscape of Related Patents and Competitors
Major Patent Holders
- Large Pharma: Companies such as Novartis, Pfizer, and Roche often file patents in Spain for innovative formulations.
- Academic & Small Biotech: Universities and startups frequently contribute early-stage patents for novel compounds or delivery systems.
Patent Clusters
- Several patents exist claiming similar active ingredients or targeted therapeutic indications, leading to a crowded landscape.
- Patent families often include multiple jurisdictions and formulations, indicating strategic geographic coverage.
Legal Status and Litigation
- No public records indicate ongoing litigation involving ES2539285.
- Patents in similar spaces face challenges primarily related to novelty or inventive step, with oppositions common during European opposition periods.
Key Legal and Strategic Factors
- Novelty: Claims must differ significantly from prior art to avoid novelty rejections.
- Inventive Step: The inventive step must be non-obvious over existing therapies or formulations.
- Extensions and Market Exclusivity:
- Regulatory Exclusivity: Data or market exclusivity post-approval can extend market protection beyond patent life.
- SPC (Supplementary Protection Certificate): Possible in the EU where applicable, extending patent protection by up to 5 years.
Conclusions
ES2539285 claims a pharmaceutical composition, likely involving a specific combination or formulation, with a strategic filing history aligned to maximize protection within Europe and globally. The landscape is crowded with similar patents, requiring precise claim drafting to maintain enforceability. Patent expiration is anticipated around 2030–2033, fitting within typical lifecycle parameters.
Key Takeaways
- The patent's claims focus on a specific pharmaceutical composition, with scope determined by active ingredients, formulation, or method.
- The patent landscape involves multiple jurisdictions, with filings aimed at broad international protection.
- The main competitors are large pharma companies and biotech innovators holding related patents.
- Patent validity depends on novelty and inventive step over existing art; continued monitoring is advised for potential challenges.
FAQs
1. How broad are the claims in ES2539285?
Claims are likely narrow, focusing on a specific active ingredient combination or presentation, but may include broader use or method claims.
2. When does the patent ES2539285 expire?
Expected around 2030–2033, contingent on the filing date and any extensions or supplementary protections.
3. Are there related patents in other jurisdictions?
Yes. Patent families often include filings in the US, Europe, and Japan to ensure counterparts in key markets.
4. How does the patent landscape affect potential development?
A crowded patent space requires careful freedom-to-operate analysis; overlapping claims may lead to licensing or clearance challenges.
5. What are the main strategic considerations for patenting in Spain?
Aligning claims with patentability requirements, considering extensions like SPCs, and ensuring comprehensive coverage through family filings are crucial.
References
- European Patent Office. Patent data and statistics. (2022).
